In a study, overweight people lost 35 to 52 kilograms with a newly approved anti-diabetic drug.

Tirzepatide sold under the Mounjaro brand has been studied in three doses in people without diabetes: 5, 10 and 15 milligrams. Participants who were obese or overweight lost an average of 35 pounds (16 kilograms) at a dose of 5 milligrams, 49 pounds (22 kilograms), and 15 milligrams at an average dose of 10 milligrams. The dose lost an average of 52 pounds (23.6 pounds).

“Almost 40% of people have lost a quarter of their body weight,” says one of the authors. Ania Jastreboff, co-director of the Yale Weight Management Center, at a media briefing.

“The data was very impressive,” the doctor said. Robert Gabbay, chief physician of the American Diabetes Association, spoke to CNN at the 82nd ADA Science Session in New Orleans and presented the findings.

“The weight loss they received in this study was greater than that seen in previous studies of people with diabetes,” said Gabbay, who did not participate in the study.

“In this new study, the average weight loss range for humans was 49 pounds – 49 pounds more,” he said. “This is the range of weight loss we usually think is only possible through surgery.”

Overall, people without diabetes lost an average of 15% to 20.9% of their initial body weight during a 72-week double-blind, randomized clinical trial published in The New England Journal of Medicine on Saturday. Participants who received a placebo lost an average of 2.4% and 3.1% of their body weight.
For comparison, in a study of people with diabetes who took tirzepatide, they lost an average of 15% of their initial body weight, Gabbay said.

“It’s not uncommon to observe,” he said. “The effects of medications for previous weight loss are less effective in people with diabetes, and we don’t really know exactly why.”

However, the effects of tirzepatide on people with diabetes are still “profound,” Gabbay said, “far more than any other weapon we have.”

self-injection dose

For the new study, weekly injections of tirzepatide were tested on more than 2,500 people without diabetes who had a body mass index (BMI) of 30 or above 27 and at least one weight-related health condition, such as high blood pressure. , high cholesterol or cardiovascular disease. A person’s height-to-weight ratio, a BMI of 25 or higher, is considered overweight in adults.

Research shows that alternative sweets in your drinks help reduce weight and the risk of diabetes.

At the beginning of the study, participants weighed an average of 231 pounds (104.8 kilograms) and had an average BMI of 38.

Adults in the study injected tirzepatide or a placebo once a week using a “tiny, pen-like device with a small, tiny needle,” Gabbay said. “It hurts less than people who inject needles, for example, to measure blood glucose.”

The study participants received counseling sessions to help them stay on a healthy diet with a daily calorie deficit of 500 calories, and exercised at least 150 minutes a week. While this certainly helps, it does not explain the amount of weight loss observed in the study, Gabbay said.

“People lose 5% to 7% of the weight they notice when they exercise and change their calories,” he said. “This study showed that lifestyle changes resulted in much higher weight loss than we thought.”

The most common side effects were dizziness, diarrhea and severe diarrhea. Between 2.6% and 7.1% of participants discontinued treatment due to adverse events.

Mounjaro carries a box warning about thyroid cancer and should not be used by people with a family history of certain thyroid conditions.

Changing your diet can prolong your life by 13 years, according to research

“Obesity needs to be treated like any other chronic disease – with effective and safe methods that target the underlying disease (causes) … and these results underscore that tirzepatide does just that,” said Jasreboff of the Yale Weight Management Center. According to the American Diabetes Association.

“These findings are an important step in expanding potentially effective treatment options for people with obesity.”


Leave a Comment

Your email address will not be published.